Spasticity in multiple sclerosis and role of glatiramer acetate treatment

Spasticity in multiple sclerosis and role of glatiramer acetate treatment

Bibliographic Details
Main Authors:	Meca-Lallana, Jose Eustasio, Hernández-Clares, Rocío, Carreón-Guarnizo, Ester
Format:	Online
Language:	English
Published:	John Wiley & Sons, Ltd 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589813/

Similar Items

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
by: Sánchez-de la Rosa, Rainel, et al.
Published: (2015)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
by: Thamilarasan, Madhan, et al.
Published: (2013)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
by: Achiron, Anat, et al.
Published: (2009)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
by: Izquierdo, Guillermo, et al.
Published: (2015)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Fernández, Oscar
Published: (2012)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
by: De Riccardis, Lidia, et al.
Published: (2016)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
by: Novotna, Bronislava, et al.
Published: (2014)

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines
by: Jongen, Peter Joseph, et al.
Published: (2016)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
by: Caporro, Matteo, et al.
Published: (2014)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
by: Waschbisch, Anne, et al.
Published: (2011)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
by: Sanchez-de la Rosa, Rainel, et al.
Published: (2013)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report
by: Onmez, Attila, et al.
Published: (2013)

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
by: Zivadinov, Robert, et al.
Published: (2015)

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
by: Rovituso, Damiano M., et al.
Published: (2015)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
by: Oreja-Guevara, Celia, et al.
Published: (2012)

Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients
by: Pul, Refik, et al.
Published: (2012)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
by: Giannini, Marta, et al.
Published: (2012)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
by: Bergvall, Niklas, et al.
Published: (2014)

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
by: Oleen-Burkey, MerriKay, et al.
Published: (2014)

Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome
by: Kuzina, Ekaterina, et al.
Published: (2014)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Published: (2015)

Glatiramer acetate treatment negatively regulates type I interferon signaling
by: Molnarfi, Nicolas, et al.
Published: (2015)

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate
by: Moore, Spencer, et al.
Published: (2014)

Leg Spasticity and Ambulation in Multiple Sclerosis
by: Balantrapu, Swathi, et al.
Published: (2014)

Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?
by: Jalilian, Babak, et al.
Published: (2012)

Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation
by: Herges, Katja, et al.
Published: (2011)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
by: Arnold, Douglas L., et al.
Published: (2013)

CD8+ T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease
by: Tyler, Andrew F., et al.
Published: (2013)

Glatiramer acetate does not protect from acute ischemic stroke in mice
by: Kraft, Peter, et al.
Published: (2014)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
by: Towfic, Fadi, et al.
Published: (2014)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
by: Ziemssen, Tjalf, et al.
Published: (2015)

A Patient Care Program for Adjusting the Autoinjector Needle Depth According to Subcutaneous Tissue Thickness in Patients With Multiple Sclerosis Receiving Subcutaneous Injections of Glatiramer Acetate
by: Masid, Maria Luisa Sánchez, et al.
Published: (2015)

A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA)
by: Høglund, Rune A., et al.
Published: (2013)

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
by: Ziemssen, Tjalf, et al.
Published: (2014)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-<i>β</i> and glatiramer acetate for multiple sclerosis
Published: (2006)

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
by: Russo, Margherita, et al.
Published: (2015)

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
by: Fernández-Fournier, Mireya, et al.
Published: (2015)

Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1
by: Janssen, Antonia, et al.
Published: (2015)

The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation
by: Mitne, Somaia, et al.
Published: (2011)

Glatiramer Acetate Treatment Increases Stability of Spinal Synapses and Down Regulates MHC I during the Course of EAE
by: Scorisa, Juliana M., et al.
Published: (2011)